La Jolla scientists at the Salk Institute say they have spotted a type of B cell that can home in on tumors and call in killer T cells to finish the job, a behavior one researcher compared to a “heat‑seeking missile” locked on target. The discovery hints at a new angle for immunotherapy against solid tumors, although the team stresses this is early-stage basic research that will need extensive follow-up work and human trials before anyone talks about a treatment.
Daniel Hollern, who is leading the project at Salk, told The San Diego Union‑Tribune that certain B cells can act like field commanders, helping direct T cells toward tumor cells. His group is probing how to restore or boost that guiding role. As the Union‑Tribune reported, the work has local philanthropic backing as it moves through discovery experiments. Lab representatives are quick to add that turning this biology into something clinically useful will take time and a fresh round of studies.
How B Cells May Steer The Immune Attack
B cells are usually cast as the body’s antibody factories, tagging viruses and bacteria so the rest of the immune system can pounce. Hollern’s team says a subset of tumor‑associated B cells appears to do something similar with cancer cells, producing antibodies that mark them and help fire up CD8 T cells, the so‑called killer T cells. The Hollern Lab at Salk describes a model in which those antibodies act like beacons and B‑cell “niches” in or near tumors help recruit and co‑activate T cells, a pathway they see as a potential therapeutic target; background on the concept is outlined in Hollern Lab research.
Where This Fits In The Field
The idea that B cells influence anti‑tumor immunity has been gathering support for several years. In 2019, Hollern co‑authored a Cell paper showing that B cells and T follicular helper cells can shape how mouse tumors respond to checkpoint inhibitor drugs. That and other recent work help explain why a new review in Cellular & Molecular Immunology calls for careful mapping of B‑cell subtypes and antibody classes before pushing candidate therapies into patient trials.
Next Steps And What To Watch
Salk researchers are set to walk through their findings and the possible therapeutic angles in an upcoming Del Mar Foundation webinar on Wednesday. The event, listed as “Turning the Immune System Against Breast Cancer,” is part of a short series that tries to connect basic lab discoveries to real‑world treatment strategies, according to the Del Mar Foundation. The Salk group and outside experts emphasize that all of this remains preclinical. Commercial labs are already testing ways to enlist B cells or fine‑tune immune targeting more broadly, including work at Johns Hopkins in which researchers recently reported nanoparticles that can “educate” T cells and redirect immune responses in mice. For now, more animal experiments and tightly designed clinical trials will be needed to test whether any approach built on this biology is safe and effective.
Scientists caution that promising immune tricks in mice often hit a wall in humans. Still, if the B‑cell seek‑and‑signal model holds up, it could help extend immunotherapy to cancers that shrug off T‑cell‑only strategies. That would be a long‑range prospect for patients, but it is already a tantalizing mechanistic lead for researchers and drug developers watching the space.
